Company's Report Entitled, 'Ingenuity at Work,' Discusses Abbott's Contributions to Access, Innovation, Science Education and the Environment
ABBOTT PARK, Ill., June 2 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today released its 2007 Global Citizenship Report, "Ingenuity at Work," which is available online at http://www.abbott.com/citizenship. The report highlights Abbott's commitment to access to care, innovation, science education and the environment.
Named to the Dow Jones Sustainability World and North American Indices in 2007 for the third consecutive year, Abbott remains a leader in economic, social and environmental performance -- with the company and the Abbott Fund contributing more than $385 million in grants and products to help improve the lives of millions of people around the world.
"To us, citizenship challenges are core business challenges -- they're
part of how we effectively develop, manufacture and market a product," said
Miles D. White, chairman and chief executive officer, Abbott. "We view
citizenship as a matter of competitiveness and business discipline. We find
it invigorating that society is demanding more of business enterprises
today, and we're energized to meet and extend these new standards."
Following are some of Abbott's major accomplishments in 2007:
Access to Care
-- Provided support and resources to clinics and laboratories in Africa to
help people in need access medical care and supplies. Abbott plans to
help modernize 23 additional laboratories in Africa in 2010.
-- Offered more than $183 million worth of free Abbott medicines,
nutritionals and medical devices through patient assistance programs
-- Invested more than $2.5 billion in research and development, an
increase of 11.1 percent from the previous year. Through medical
advancements and new scientific technologies, Abbott is tackling some
of today's most pressing chronic diseases -- diabetes, cancer and
-- Introduced the first and only co-formulated protease inhibitor tablet
suitable for children with HIV. The tablet does not require
refrigeration and does not need to be taken with food -- two important
advances in delivering HIV medicine. Kaletra (known as Aluvia in
developing countries) was filed or has been approved in 156 developed
and developing countries.
-- Supported science education in the United States through a new program
called "Labs Are Vital," which helps to raise awareness of the
life-saving work clinical laboratory professionals provide in improving
-- Launched pilot programs to enhance science education and worked closely
with teachers in several U.S. cities to promote science in the
classrooms. In 2008, Abbott aims to expand these programs across the
-- Became the first FORTUNE 500 company to go "carbon neutral" with its
fleet of sales vehicles.
-- Improved operations to help protect the environment, including reducing
carbon dioxide (CO2) emissions with plans to reduce total emissions by
30 percent by 2011.
-- Continued to work towards 2010 goals to reduce water usage, waste,
employee injuries and commercial vehicle fleet accidents to help
generate the greatest environmental, health and safety benefits.
About Abbott's 2007 Global Citizenship Report
Abbott's full 2007 report is now available online at http://www.abbott.com/citizenship, including a copy of the company's Global Reporting Initiative (GRI) Index. In order to reduce its environmental impact, the company published a shortened version of the print report and expanded the information available on its Web site. The abbreviated print version can be downloaded from the Web site or requested by email at email@example.com.
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.
Copyright©2008 PR Newswire.
All rights reserved